Raycure Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 03-01-2025
- Paid Up Capital ₹ 0.50 M
as on 03-01-2025
- Company Age 19 Year, 15 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -16.88%
(FY 2017)
- Profit 42.58%
(FY 2017)
- Ebitda 85.61%
(FY 2017)
- Net Worth -356.61%
(FY 2017)
- Total Assets 20.71%
(FY 2017)
About Raycure Drugs
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Jhamb, Veeta Sharma, and Tarsem Ruby serve as directors at the Company.
- CIN/LLPIN
U00304CH2006PLC029458
- Company No.
029458
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationU.T. Chandigarh., Chandigarh
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Raycure Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Jhamb  | Additional Director | 31-Aug-2020 | Current |
| Veeta Sharma | Director | 02-Jan-2006 | Current |
| Tarsem Ruby | Director | 02-Jan-2006 | Current |
Financial Performance of Raycure Drugs.
Raycure Drugs Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 16.88% decrease. The company also saw a substantial improvement in profitability, with a 42.58% increase in profit. The company's net worth observed a substantial decline by a decrease of 356.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raycure Drugs?
In 2017, Raycure Drugs had a promoter holding of 92.00% and a public holding of 8.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Raymed Ophthalmic Private LimitedActive 5 years 8 monthsSanjay Jhamb and Tarsem Ruby are mutual person
Raymzon Trade Links Private LimitedActive 4 years 5 monthsVeeta Sharma and Tarsem Ruby are mutual person
- Raymazon Pharmalinks Private LimitedActive 4 years 6 months
Veeta Sharma and Tarsem Ruby are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Raycure Drugs?
Unlock and access historical data on people associated with Raycure Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raycure Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raycure Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
